Solid Biosciences (SLDB) Competitors $5.39 +0.08 (+1.51%) Closing price 04:00 PM EasternExtended Trading$5.44 +0.06 (+1.02%) As of 06:45 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock SLDB vs. APGE, BHVN, CDTX, PAHC, AUPH, ARDX, EWTX, TWST, COGT, and AVDLShould you be buying Solid Biosciences stock or one of its competitors? The main competitors of Solid Biosciences include Apogee Therapeutics (APGE), Biohaven (BHVN), Cidara Therapeutics (CDTX), Phibro Animal Health (PAHC), Aurinia Pharmaceuticals (AUPH), Ardelyx (ARDX), Edgewise Therapeutics (EWTX), Twist Bioscience (TWST), Cogent Biosciences (COGT), and Avadel Pharmaceuticals (AVDL). These companies are all part of the "pharmaceutical products" industry. Solid Biosciences vs. Its Competitors Apogee Therapeutics Biohaven Cidara Therapeutics Phibro Animal Health Aurinia Pharmaceuticals Ardelyx Edgewise Therapeutics Twist Bioscience Cogent Biosciences Avadel Pharmaceuticals Apogee Therapeutics (NASDAQ:APGE) and Solid Biosciences (NASDAQ:SLDB) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their institutional ownership, risk, earnings, profitability, analyst recommendations, dividends, valuation and media sentiment. Do analysts rate APGE or SLDB? Apogee Therapeutics presently has a consensus target price of $97.29, suggesting a potential upside of 163.79%. Solid Biosciences has a consensus target price of $15.00, suggesting a potential upside of 178.29%. Given Solid Biosciences' stronger consensus rating and higher probable upside, analysts plainly believe Solid Biosciences is more favorable than Apogee Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Apogee Therapeutics 0 Sell rating(s) 1 Hold rating(s) 7 Buy rating(s) 0 Strong Buy rating(s) 2.88Solid Biosciences 0 Sell rating(s) 0 Hold rating(s) 10 Buy rating(s) 1 Strong Buy rating(s) 3.09 Do insiders & institutionals hold more shares of APGE or SLDB? 79.0% of Apogee Therapeutics shares are owned by institutional investors. Comparatively, 81.5% of Solid Biosciences shares are owned by institutional investors. 42.8% of Apogee Therapeutics shares are owned by company insiders. Comparatively, 1.9% of Solid Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term. Does the media prefer APGE or SLDB? In the previous week, Apogee Therapeutics had 6 more articles in the media than Solid Biosciences. MarketBeat recorded 13 mentions for Apogee Therapeutics and 7 mentions for Solid Biosciences. Solid Biosciences' average media sentiment score of 1.64 beat Apogee Therapeutics' score of 1.21 indicating that Solid Biosciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Apogee Therapeutics 8 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Solid Biosciences 5 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Which has more volatility & risk, APGE or SLDB? Apogee Therapeutics has a beta of 1.42, suggesting that its stock price is 42% more volatile than the S&P 500. Comparatively, Solid Biosciences has a beta of 2.54, suggesting that its stock price is 154% more volatile than the S&P 500. Which has stronger earnings & valuation, APGE or SLDB? Apogee Therapeutics is trading at a lower price-to-earnings ratio than Solid Biosciences, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioApogee TherapeuticsN/AN/A-$182.15M-$4.13-8.93Solid BiosciencesN/AN/A-$124.70M-$2.80-1.93 Is APGE or SLDB more profitable? Apogee Therapeutics' return on equity of -34.65% beat Solid Biosciences' return on equity.Company Net Margins Return on Equity Return on Assets Apogee TherapeuticsN/A -34.65% -32.76% Solid Biosciences N/A -69.70%-56.74% SummarySolid Biosciences beats Apogee Therapeutics on 10 of the 14 factors compared between the two stocks. Get Solid Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for SLDB and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding SLDB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart SLDB vs. The Competition Export to ExcelMetricSolid BiosciencesMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$413.48M$3.12B$5.79B$10.15BDividend YieldN/A2.32%5.69%4.61%P/E Ratio-1.9321.3074.5925.92Price / SalesN/A240.30449.5483.33Price / CashN/A45.3337.0859.91Price / Book1.579.6112.156.29Net Income-$124.70M-$53.29M$3.28B$270.85M7 Day Performance-2.00%0.29%0.98%3.36%1 Month Performance-10.76%8.91%7.20%6.41%1 Year Performance-30.18%13.14%63.06%28.26% Solid Biosciences Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)SLDBSolid Biosciences2.9954 of 5 stars$5.39+1.5%$15.00+178.3%-29.1%$413.48MN/A-1.93100Positive NewsAPGEApogee Therapeutics2.9079 of 5 stars$36.82-3.5%$97.29+164.3%-26.4%$1.70BN/A-8.9191News CoveragePositive NewsBHVNBiohaven3.2653 of 5 stars$15.91-1.9%$55.71+250.3%-60.4%$1.68BN/A-2.07239Trending NewsGap DownCDTXCidara Therapeutics3.2774 of 5 stars$63.82+0.6%$64.14+0.5%+458.3%$1.62B$1.27M-5.7490Positive NewsPAHCPhibro Animal Health4.5228 of 5 stars$39.56+3.6%$28.40-28.2%+101.4%$1.60B$1.30B33.531,940Trending NewsInsider TradeAnalyst RevisionAUPHAurinia Pharmaceuticals2.9574 of 5 stars$12.16+1.4%$12.00-1.3%+95.7%$1.60B$235.13M28.27300News CoveragePositive NewsARDXArdelyx4.6206 of 5 stars$6.44-1.2%$11.70+81.8%+12.1%$1.55B$333.61M-27.9890Positive NewsEWTXEdgewise Therapeutics2.796 of 5 stars$14.50-0.9%$40.55+179.6%-12.9%$1.52BN/A-9.3360Positive NewsTWSTTwist Bioscience3.978 of 5 stars$25.21-3.0%$49.40+95.9%-42.3%$1.52B$362.27M-17.40990News CoverageCOGTCogent Biosciences2.8699 of 5 stars$12.93-1.2%$20.00+54.7%+19.6%$1.47BN/A-7.2680Positive NewsAVDLAvadel Pharmaceuticals2.8913 of 5 stars$14.68+0.1%$19.14+30.4%+16.2%$1.43B$169.12M-489.3370 Related Companies and Tools Related Companies Apogee Therapeutics Competitors Biohaven Competitors Cidara Therapeutics Competitors Phibro Animal Health Competitors Aurinia Pharmaceuticals Competitors Ardelyx Competitors Edgewise Therapeutics Competitors Twist Bioscience Competitors Cogent Biosciences Competitors Avadel Pharmaceuticals Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:SLDB) was last updated on 9/12/2025 by MarketBeat.com Staff From Our PartnersStunning new initiative unfolding in the White House?what I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredCritical AI announcement set to ignite AI 2.0I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredForget NVDA. Put $1,000 into this stock nowA massive money shift is underway in the AI market. And it's opening up an extraordinary opportunity in a NEW ...Chaikin Analytics | SponsoredIRS Wants Another Check on Sept 15th—What If You Could Keep It Instead?On September 15th, the IRS collects another round of quarterly tax payments—targeting self-employed profession...American Alternative | SponsoredOut of 18,347 Cryptocurrencies... This is the ONLY OneThe Single Most Undervalued DeFi Protocol You've Never Heard Of If there's one cryptocurrency you should b...Crypto 101 Media | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredDo NOT Day Trade (Do THIS instead)Forget day trading (especially in markets like these). Trade OVERNIGHT instead! I've uncovered a shockin...Monument Traders Alliance | SponsoredWall Street laughed at Trump’s “Smart Dollar.” Now they’re all in."THIS is the Biggest Economic Story of 2025" While most Americans are focused on tariffs and inflation, the...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Solid Biosciences Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Solid Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
